October will end, and another multinational pharmaceutical company will disclose its third-quarter financial report!

Entering the end of October, the first three quarters of listed companies' financial reports have also surfaced
.
As far as the disclosure of multinational pharmaceutical companies is concerned, as of now, Eli Lilly, Novartis, Johnson & Johnson, Roche, Bojian and other companies have announced their three-quarter financial reports.
The overall performance is mixed.
Some companies have achieved certain growth in their innovative drug business, such as Johnson & Johnson's top three.
Quarterly sales of the pharmaceutical business were US$12.
994 billion, a year-on-year increase of 13.
8%.
Its blockbuster anti-inflammatory drug Stelara, CD38-targeted AIDS drug Darzalex, BTK inhibitor Imbruvica, and psoriasis drug Tremfya performed well in the first three quarters; Novartis's innovative drug business net sales were US$10.
628 billion, an increase of 8% year-on-year
.
On October 28th, Teva Pharmaceuticals, a US-listed company, also released its third quarterly report for the 2021 fiscal year
.
Teva Pharmaceuticals’ financial reports for the first three quarters show that from January to September 2021, the company achieved operating income of US$11.
778 billion, a year-on-year decrease of 3.
51%, and net profit attributable to the parent company of US$576 million, which turned losses into profits year-on-year, with a loss of US$4.
140 billion in the same period last year.
, Basic earnings per share is $0.
52
.
From the perspective of the industry, compared with the same period last year, Teva Pharmaceutical’s profitability and cash flow have improved.
During the reporting period, the company’s total assets at the end of the period were 47.
851 billion U.
S.
dollars, pre-tax profit was 833 million U.
S.
dollars, and net cash flow from operating activities.
The amount is 342 million U.
S.
dollars
.
For a long time, Teva Pharmaceuticals has been regarded by the outside world as a "generic drug boss
.
" In addition to generic drugs, a series of original new drugs are gradually opening up the market in recent years
.
For example, it can be seen from the 2021 mid-year report that the sales of its Huntington's disease treatment drug Austedo have increased compared with the second quarter of 2020; the global net sales of migraine prevention drug Ajovy have also increased to 70 million US dollars; The market share of similar drugs Truxima in the U.
S.
continues to grow to 25%
.
It is worth mentioning that for many years, Teva’s core income has relied on Copaxone, an original drug for the treatment of multiple sclerosis.
The sales of this product have been rising since 1996, and reached 42 US dollars in 2016.
However, with the expiration of the patent in 2015, the product faced the impact of Sandoz, Mylan and Indian generic drug companies, and the product revenue began to decline sharply.
In the second quarter report of Teva Pharmaceuticals in 2021, Copaxone was in North America.
The revenue has dropped by 36% year-on-year
.
For this reason, the company chose to put its main products on the other two original research drugs, Austendo and Ajovy, and launched a biosimilar drug Truxima in North America in 2019
.
As of the second quarter of this year, Austedo's revenue in North America has increased by 8% year-on-year, and Ajovy's revenue in Europe has tripled year-on-year
.
But industry insiders also pointed out that Ajovy also faces competition from Eli Lilly and Amgen in the field of migraine
.
Up to now, the company's technology platform includes biosimilar drugs, new biological agents, small molecule drugs and digital respiratory systems
.
In addition to generic drugs, Teva's specialty drugs and biosimilar drug product pipelines also cover the respiratory system, pain, migraine and headache, sports and neurodegenerative diseases, and tumors
.
It is reported that in the company’s current product pipeline, one adalimumab biosimilar is in the regulatory review stage, two respiratory drugs, one schizophrenic drug, and one biosimilar are in the pre-submission stage.
There are 11 drugs in the clinical stage
.
Public information shows that Teva Pharmaceuticals is a company registered in Israel dedicated to the research, development, production and promotion of generic drugs, branded drugs and active pharmaceutical ingredients
.
The company sells drugs in various dosages, including extended and direct-release tablets and capsules, creams, ointments, and formulations
.
The company's main treatment scope covers analgesics, anti-infection, cardiovascular, CNS, skin diseases and anti-inflammatory, etc.
, and currently sells its products to customers such as chain stores, wholesalers, distributors, hospitals, nursing homes and government agencies
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina","tqq"," tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:", "viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu", "tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}};with(document)0[(getElementsByTagName('head ')[0]||body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js ?cdnversion='+~(-new Date()/36e5)]; Keywords: October will end, and another multinational pharmaceutical company will disclose its third-quarter financial report! , Multinational pharmaceutical companies, three quarterly report Next: my country’s vaccine market is about to exceed 60 billion yuan, and more requirements will be placed on this industry.
Previous: Recently, many large pharmaceutical companies’ new drug R&D projects have been terminated [Information Search] [Add to Favorites] [Tell a friend] [Print this article] [Close window] There are 0 pieces of similar information [View all] Related comments js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; Keywords: October will end, and another multinational pharmaceutical company will disclose its third quarter financial report! , Multinational pharmaceutical companies, three quarterly report Next: my country’s vaccine market is about to exceed 60 billion yuan, and more requirements will be placed on this industry.
Previous: Recently, many large pharmaceutical companies’ new drug R&D projects have been terminated [Information Search] [Add to Favorites] [Tell a friend] [Print this article] [Close window] There are 0 pieces of similar information [View all] Related comments js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; Keywords: October will end, and another multinational pharmaceutical company will disclose its third quarter financial report! , Multinational pharmaceutical companies, three quarterly report Next: my country’s vaccine market is about to exceed 60 billion yuan, and more requirements will be placed on this industry.
Previous: Recently, many large pharmaceutical companies’ new drug R&D projects have been terminated [Information Search] [Add to Favorites] [Tell a friend] [Print this article] [Close window] There are 0 pieces of similar information [View all] Related comments